– Sale increase of all divisions, including 40% YOY increase in CARTISTEM^® sales
– Significance of turning to profit even after handling the R&D expenses

MEDIPOST announced on the May 3 that its operating profit and net profit both had turned to a profit with the highest quarterly sales in the 1Q of this year.

MEDIPOST’s separate quarterly sales grew by 7.2% compared to the previous year to 12,329 billion won, with operating profit of 337 million won and a net profit of 814 million won, it has turned from loss to profits respectively, operating loss and net lost with 2,866 billion won and 2.66 billion won at the same time last year.

When looking at each business division, CARTISTEM^®‘s sales soared by 40% in comparison to the previous year to a driving sales growth, and sales evenly increased for the entire business division such as the sales of the umbilical cord blood banks hitting record with a two-digit growth.

In particular, quarterly sales volume surpassed 1000 vials for the first time such as CARTISTEM^®’s monthly sales volume reached the highest record each month in January-March, and this is a green light for reaching the yearly goal.
Also, the umbilical cord blood bank reached quarterly sales of more than 6 billion won after four years, showing that it will ensure to maintain being number one in domestic market share firmly.

A MEDIPOST representative said, “it was significant that the company succeeded in turning into profit even after all R&D expenses were processed according to the financial authorities’ accounting standards last year,” and that “We will adhere to continuously invest in the future for the launch of new R&D project, enlargement of production line, etc.”